1. Home
  2. SBFG vs KRRO Comparison

SBFG vs KRRO Comparison

Compare SBFG & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SB Financial Group Inc.

SBFG

SB Financial Group Inc.

N/A

Current Price

$27.31

Market Cap

182.2M

Sector

Finance

ML Signal

N/A

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

SELL

Current Price

$12.23

Market Cap

196.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SBFG
KRRO
Founded
1983
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.2M
196.4M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
SBFG
KRRO
Price
$27.31
$12.23
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $21.50
AVG Volume (30 Days)
12.8K
★ 199.8K
Earning Date
10-22-2026
11-05-2026
Dividend Yield
★ 2.29%
N/A
EPS Growth
★ 27.33
N/A
EPS
★ 2.04
N/A
Revenue
N/A
★ $6,392,000.00
Revenue This Year
$5.46
N/A
Revenue Next Year
$2.35
N/A
P/E Ratio
$13.76
★ N/A
Revenue Growth
N/A
★ 181.46
52 Week Low
$19.54
$5.20
52 Week High
$32.63
$17.35

Technical Indicators

Market Signals
Indicator
SBFG
KRRO
Relative Strength Index (RSI) 35.80 44.39
Support Level $20.66 $11.81
Resistance Level $27.56 $14.47
Average True Range (ATR) 1.36 1.42
MACD -0.22 -0.44
Stochastic Oscillator 5.88 12.39

Price Performance

Historical Comparison
SBFG
KRRO

About SBFG SB Financial Group Inc.

SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: